Company: STAA
Filing Date: 2025-09-16
Form Type: DEFM14A
Source: 0001193125-25-204396
Chunk: 86

Company: STAAR SURGICAL CO
Filing Date: 2025-09-16
Form: DEFM14A
Chunk 86
---
 |     | the fact that some of STAAR’s directors and executive officers have interests in the Merger that are                                                                                                             
 different from, or in addition to, STAAR stockholders generally (as further described in the section of this proxy statement titled “—Interests of STAAR’s Executive Officers and Directors in the Merger”); and |

| • |     | the fact that STAAR’s remedies in the event that the Merger Agreement is terminated may be limited to the                                                                                                                                               
 Alcon Termination Fee of $72,375,000 in certain circumstances and certain other damages, associated enforcement costs and other indemnification and reimbursement obligations, which may be inadequate to compensate STAAR and its stockholders for any 
 damage caused, and that the Alcon Termination Fee may not be payable in all instances where the Merger is not consummated and, even if payable, the success of any such action to cause such payment may be uncertain.                                  |

The foregoing discussion of factors considered by the Board is not intended to be exhaustive, but rather includes the material factors considered by the Board. In reaching its decision that the Merger Agreement and the transactions contemplated thereby, including the Merger, on the terms and subject to the conditions set forth in the Merger Agreement, are advisable, fair to and in the best interests of STAAR and its stockholders, approved, -52-

adopted and declared advisable the execution and delivery of, and entry into, the Merger Agreement, and directed that the Merger Agreement be submitted to the STAAR stockholders for adoption at the Special Meeting, the Board did not quantify, rank or otherwise assign any relative weights to, and did not make specific assessments of, the factors considered, and individual directors may have given different weights to different factors. The Board did not reach any specific conclusion with respect to any of the factors or reasons considered, but determined, in its business judgment, that, in the aggregate, the potential benefits it considered outweighed the potential risks or possible negative consequences of approving the Merger Agreement, the Merger and the other transactions contemplated by the Merger Agreement. The above factors are not presented in any order of priority. The explanation of the factors and reasoning set forth above contain forward-looking statements and should be read in conjunction with the section of this proxy statement titled “ Special Note Regarding Forward-Looking Statements.” Opinion of STAAR’s Financial Advisor STAAR retained Citi as its financial advisor in connection with a possible transaction involving Alcon. In connection with Citi